Craft

Ipsen

Stock Price

€107.8

2024-02-09

Market Capitalization

€8.9 B

2024-02-09

Revenue

€3.2 B

FY, 2022

Ipsen Summary

Company Summary

Overview
Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014 in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumors. Ipsen also has a significant presence in primary care. The Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative technological platforms, peptides and toxins, located in the heart of the leading biotechnological hubs (Les Ulis, Fr ; Slough/Oxford, UK ; Cambridge, US). In 2014, R&D expenditure totaled close to €187 million (about 15% of Group sales). The Group has more than 4,500 employees.
Type
Public
Status
Active
Founded
1929
HQ
Boulogne-Billancourt, FR | view all locations
Website
https://www.ipsen.com/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Aymeric le Chatelier

    Aymeric le Chatelier, EVP, Group CFO

  • Marc de Garidel
  • David Loew

    David Loew, Chief Executive Officer

  • Shahrzad Amirani

    Shahrzad Amirani, Vice President, Head of New Products and Innovation

LocationsView all

49 locations detected

  • Boulogne-Billancourt, IDF HQ

    France

    65 Quai Georges Gorse

  • Berkeley Heights, NJ

    United States

    200 Connell Drive Suite

  • Cambridge, MA

    United States

    One Kendall Square

  • Cambridge, MA

    United States

    One Main Street

  • Algiers, Wilaya d'Alger

    Algeria

    9 Chem. de Val d'Hydra

  • South Yarra, VIC

    Australia

    627 Chapel St

and 43 others

Ipsen Financials

Summary Financials

Revenue (H1, 2023)
€1.5B
Gross profit (H1, 2023)
€1.5B
Net income (H1, 2023)
€205.4M
Cash (H1, 2023)
€413.4M
EBIT (H1, 2023)
€295.5M
Enterprise value
$9.2B

Footer menu